Diabetes Experts Respond to New Clinical Trials

Key points
- The American Association of Clinical Endocrinologists (AACE) has been closely monitoring the results of two major clinical trials released this week, ADVANCE and ACCORD.
- •The recommended A1c target should remain 6.5% for most patients – While the ACCORD study did show increased mortality for some patients in the most intensive glycemic control arm of the study, no conclusions have been made to modify current clinical goals.
- •No patient should change their treatment plan without consulting their physician – While ACCORD may suggest a change in treatment goals for some people, it will not affect the treatment plans of most patients with diabetes.
- •The ADVANCE study confirms evidence of the microvascular benefits of tight glycemic control – The ADVANCE study shows a significant decrease in microvascular complications associated with tight glycemic control.
The American Association of Clinical Endocrinologists (AACE) has been closely monitoring the results of two major clinical trials released this week, ADVANCE and ACCORD. The results of the studies highlight controversy concerning the benefits and risks of tight glycemic control. As a result, some patients with type 2 diabetes may be confused about what their treatment goals should be. That is why AACE, the world’s largest association of clinical endocrinologists, is making the following recommendations.
•The recommended A1c target should remain 6.5% for most patients – While the ACCORD study did show increased mortality for some patients in the most intensive glycemic control arm of the study, no conclusions have been made to modify current clinical goals. It is important to note that the number of non-fatal myocardial infarctions was reduced in the intensive treatment arm. AACE supports further research of the high-risk populations included in this study to determine if different therapeutic targets may be appropriate for certain individuals.
•No patient should change their treatment plan without consulting their physician – While ACCORD may suggest a change in treatment goals for some people, it will not affect the treatment plans of most patients with diabetes. Patient who choose to discontinue or alter their prescribed treatment regimens on their own may increase their risk of complications of diabetes including retinopathy, nephropathy, and neuropathy.
•The ADVANCE study confirms evidence of the microvascular benefits of tight glycemic control – The ADVANCE study shows a significant decrease in microvascular complications associated with tight glycemic control. These results confirm the findings in numerous prior studies.
Achieving and maintaining optimal glycemic control is crucial in the prevention of complications associated with type 2 diabetes. But these goals can not be achieved simply with medication alone. Healthy nutrition and physical activity are essential for safely achieving blood sugar control. Patients should monitor their blood sugar regularly as prescribed and see their diabetes professionals regularly.
To access the complete AACE Clinical Practice Guidelines for the Management of Diabetes Mellitus, go to http://www.aace.com/pub/guidelines.
About AACE
AACE is a professional medical organization with more than 6,000 members in the United States and 84 other countries. Founded in 1991, AACE is dedicated to the optimal care of patients with endocrine problems. AACE initiatives inform the public about endocrine disorders. AACE also conducts continuing education programs for clinical endocrinologists, physicians whose advanced, specialized training enables them to be experts in the care of endocrine disease, such as diabetes, thyroid disorders, growth hormone deficiency, osteoporosis, cholesterol disorders, hypertension and obesity.
Written and revised by
David Cohen, M.D.
Our doctors write and review articles for accuracy and keep them up to date.
health.am provides general information, not medical advice. Always consult a qualified health professional about your own health.
Explore health topics
More in this topic
Diabetes & Hormones →
NewsInsulin pill may delay type 1 diabetes in some
It's often said that timing is everything. New research suggests this may be true when giving an insulin pill to try to prevent or delay type 1 diabetes. Researchers tested the effect of insulin pills on 560 children…
22 November 2017
NewsOneTouch Via enabled diabetes patients to report improved insulin dose compliance
People with type 1 and type 2 diabetes who used the new OneTouch Via™ mealtime, on-demand insulin delivery system reported they missed fewer doses and felt less stress about dosing compared to multiple daily injections,…
12 June 2016
NewsRice study details stress-diabetes link
A Rice University study has found a link between emotional stress and diabetes , with roots in the brain's ability to control anxiety. That control lies with the brain's executive functions, processes that handle…
7 June 2016




